Background Leigh syndrome is a phenotypically and genetically heterogeneous mitochondrial disorder. While some genetic defects are associated with well-described phenotypes, phenotype-genotype correlations in Leigh syndrome are not fully explored.
Objective We aimed to identify phenotype-genotype correlations in Leigh syndrome in a large cohort of systematically evaluated patients.
Methods We studied 96 patients with genetically confirmed Leigh syndrome diagnosed and followed in eight European centres specialising in mitochondrial diseases.
Results We found that ataxia, ophthalmoplegia and cardiomyopathy were more prevalent among patients with mitochondrial DNA defects. Patients with mutations in MT-ND and NDUF genes with complex I deficiency shared common phenotypic features, such as early development of central nervous system disease, followed by high occurrence of cardiac and ocular manifestations. The cerebral cortex was affected in patients with NDUF mutations significantly more often than the rest of the cohort. Patients with the m.8993T>G mutation in MT-ATP6 gene had more severe clinical and radiological manifestations and poorer disease outcome compared with patients with the m.8993T>C mutation.
Conclusion Our study provides new insights into phenotype-genotype correlations in Leigh syndrome and particularly in patients with complex I deficiency and with defects in the mitochondrial ATP synthase.
- Leigh syndrome
- mitochondrial DNA
- complex I
Statistics from Altmetric.com
Leigh syndrome is an early-onset progressive neurodegenerative disorder, associated with defects of mitochondrial oxidative phosphorylation. It is the most common, distinct phenotype among oxidative phosphorylation disorders in children with an estimated preschool incidence in western Sweden of 1 per 34 000 births.1 The disease is typically characterised by subacute onset of psychomotor regression and encephalopathy associated with the development of bilateral symmetrical lesions in the striatum and brainstem, which are the hallmark of the disease.2 Leigh disease is genetically highly heterogeneous as evidenced by the more than 75 genes, encoded either by the mitochondrial or the nuclear genome, that are implicated in this disorder, with more than one-third of these genes identified in the past 5 years.3
Some genotypes causing Leigh syndrome are associated with clear and well-described phenotypic traits, such as cytochrome oxidase (COX) deficiency with SURF1 mutations,4 methylmalonic aciduria with mutations in SUCLA2 5 6 and biotin-thiamine-responsive basal ganglia disease caused by mutations in the SLC19A3 gene.7 8 Other genetic defects show weaker correlation with clinical phenotype, particularly as the same mutant protein may result in highly variable clinical presentations and disease outcomes.9 For example, the m.8993T>C mitochondrial DNA (mtDNA) mutation has been associated with a less severe phenotype characterised by later onset and slower disease progression than the m.8993T>G mutation.10 11 However, the impact of each of these mutations on survival outcomes and MRI phenotypes has not been investigated.
Mitochondrial respiratory chain disorders and Leigh syndrome in particular are multisystem disorders. Cardiac involvement is common and occurs in 17%–40% of patients with mitochondrial disease.12 13 Neonatal or infantile hypertrophic cardiomyopathy has been associated with mutations in NDUFS2,14 NDUFV2,15 NDUFA11,16 NDUFS4,17 NDUFA2 18 and ACAD9,19 and can occur as an isolated finding in nuclear-encoded complex I deficiency or in combination with encephalopathy, myopathy and/or lactic acidosis. Biochemical investigations show that complex I deficiency is common in Leigh syndrome, with isolated complex I deficiency found in as many as 37% in some studies.2 20 21 Associations between complex I deficiency in Leigh syndrome and disease-specific clinical and radiological outcomes have, however, not been studied in large cohorts and nor has the incidence of cardiomyopathy or its impact on survival.
In a previous study on the natural history of Leigh syndrome, we included 130 patients, of whom 77 had genetic diagnosis at the time of publication.20 Since then, more of these patients have been clarified genetically allowing us to study associations between the genotypes and associated clinical outcomes. The aims of this study were (A) to identify phenotypic features that may differentiate between mtDNA and nuclear DNA (nDNA) associated Leigh syndrome and (B) to study distinct phenotypes and overlapping phenotypic features across the different genetic subgroups. In order to address these research questions, we studied patients’ clinical characteristics, biochemical findings, neuroimaging data and disease outcomes across the different genetic subgroups. Our findings suggest a strong association between certain genetic defects and the phenotype and disease outcome of Leigh syndrome.
Study design and population
The present study is part of a large cohort study performed within the Mitochondrial Clinical and Research Network. The study was conducted at eight European centres in Gothenburg, Rotterdam, Helsinki, Copenhagen, Stockholm, Brussels, Bergen and Oulu. These are national expert/reference centres specialising in mitochondrial diseases. We included patients with Leigh syndrome who were diagnosed and followed at the participating centres and fulfilled the inclusion criteria: (1) clinical features compatible with Leigh syndrome, for example, psychomotor regression, dystonia, ataxia and/or brainstem dysfunction and (2) MRI or CT or neuropathological findings of Leigh syndrome as follows: bilateral symmetrical lesions in the basal ganglia, and/or thalamus, and/or brainstem. Patients were excluded from the study if they had known mitochondrial phenotypes other than Leigh syndrome. Patient data were collected with the help of electronic data capture. The methodology along with longitudinal natural history data on the overall study population of 130 patients is described elsewhere.20
We used whole exome sequencing either alone or after targeted sequencing or gene-panel sequencing failed to identify the cause. While ours was not a population-based study, the results reflect the genetic diversity found in these areas of Europe.
Muscle pathology suggestive of mitochondrial myopathy was considered with any one of the following findings: mitochondrial proliferation or structurally abnormal mitochondria on light and/or electron microscopy, ragged red fibres and abnormal oxidative staining (ie, COX; succinate dehydrogenase (SDH); nicotinamide adenine dinucleotide reductase (NADH); Mg-ATPase). The following muscle findings were considered non-specific: fibre atrophy (type I or II or combined), infiltration of macrophages or T cells and lipid accumulation.
The statistical evaluations performed were mainly exploratory. Survival outcomes were estimated with the help of Kaplan-Meier analysis. χ2 test was used to test the association between categorical variables. All statistical tests were two sided and performed at a 0.05 significance level.
Here we present the results from 96 patients with genetically verified Leigh syndrome. The geographic distribution and genetic variability of our patients is depicted in figure 1. Sixty-five patients had Leigh syndrome caused by mutations in nuclear genes, while 31 patients had mtDNA-associated disease. Most patients were of Caucasian origin (68/96).
nDNA-associated Leigh syndrome
We studied 65 patients (43 male; 22 female) with Leigh syndrome due to nDNA mutations. The median age of onset was 5 months (range: from intrauterine to 10.6 years). Hypotonia was the most common feature of nDNA-associated Leigh syndrome (55/65), followed by dyskinesia (40/65) and hypertonia and/or spasticity (34/65). Ataxia was less common (16/65). Ocular involvement was seen in more than half of these patients (35/65), including nystagmus (15), optic atrophy (13), strabismus (11), visual impairment (9), ophthalmoplegia (7), retinopathy (5), saccadic eye movement (2), abnormal pupillary reflex (2) and diplopia (1). Eleven patients developed heart disease as follows: cardiomyopathy (5), arrhythmias (3), heart valve disease (2) and conduction defect (1). Sensorineural hearing loss was common (18/65) mainly in patients with defects in SUCLA2, SUCLG1 and SERAC1.
Eight distinct genetic subgroups were identified, as shown in table 1. Six patients did not fit into any of these subgroups. They had the following genetic defects: BCS1L (1/6); c12orf65 (1/6); ECHS1 (1/6); ETHE1 (1/6); PNPT1 (1/6); and TSFM (1/6).
Mitochondrial changes on muscle biopsy were found in the majority of patients with SURF1 defects (5/7), including COX deficiency (4/7) and mitochondrial proliferation (2/7). Among the other genetic subgroups, mitochondrial abnormalities in muscle were less common (12 patients, table 1). The group overall muscle pathology findings included COX deficiency (5), SDH deficiency (4), abnormal NADH staining (2), mitochondrial proliferation (1) and structurally abnormal mitochondria on electron microscopy (1).
Mutations in the nuclear-encoded subunits of the NADH:ubiquinone oxidoreductase causing complex I deficiency (NDUF group) were associated with the following distinct phenotypes.
NDUF-associated phenotypes (n=12)
The genotypic spectrum involved mutations in the following genes: NDUFS4 (2/12), NDUFS7 (2/12), NDUFV2 (2/12), NDUFAF2 (2/12), NDUFAF5 (2/12), NDUFA9 (1/12) and NDUFA12 (1/12). Four patients were of Caucasian origin, while the remainder were from North Africa and the Middle East. The most common presenting signs were hypotonia (8) and nystagmus (4). Two patients had hypertrophic cardiomyopathy at disease onset, with mutations in NDUFV2 (1) and NDUFS4 (1) genes.
The disease course was characterised by hypotonia (11), hypertonia or spasticity (8) and dystonia (7). In addition to nystagmus (6), patients developed strabismus (3), optic atrophy (3), visual impairment (3), ophthalmoplegia (1), retinopathy (1) and abnormal saccadic eye movement (1). Intellectual disability was found in all tested patients (7/7) and was severe or profound in 5 of them. Six patients suffered from respiratory complications, mainly central hypoventilation. Six patients developed heart disease as follows: hypertrophic and/or dilated cardiomyopathy (3/5), mitral valve insufficiency (1/5), pulmonary stenosis (1/5) and conduction defect (1/5). Four patients presented renal abnormalities, including kidney dysplasia (renomegaly (1) and renal aplasia (1)), abnormal renal vein anatomy (1) and renal tubular acidosis (1). These were the only patients in our cohort with renal involvement, underlying that patients with mutations in NDUF genes had significantly higher risk of developing kidney disease or dysplasia (p<0.0005).
All patients in the NDUF group had complex I deficiency (12/12), 3 in combination with complex II or complex III deficiencies. Two patients had abnormal muscle pathology findings suggestive of mitochondrial myopathy, one with enzyme histochemical SDH deficiency and another with combined SDH and COX deficiencies.
Neuroimaging of the brain revealed involvement of the deep grey matter in all patients, with lesions extending to more than one of the deep grey matter structures (9/12) (table 1). Infratentorial involvement was less common (3/12). The cerebral cortex was affected in seven patients as follows: frontal, temporal or generalised cortical atrophy (4), T2 signal hyperintensity (2), stroke-like lesions involving the frontal lobe unilaterally (1) and increased lactate signal in the entire cerebrum on spectroscopy (1). The cortical involvement found in the NDUF group was significantly more prevalent compared with the other genetic subgroups (p=0.0005).
Six patients, with a median age of 18.5 years, were still living while the remaining six patients died at a median age of 10.5 months. The latter had mutations in NDUFAF2 (2/6), NDUFA9 (1/6), NDUFS4 (1/6), NDUFS7 (1/6) and NDUFV2 (1/6). They developed multisystem disease with generalised or partial epileptic seizures (5/6), central hypoventilation (5/6), heart disease (4/6) and renal involvement (3/6). Increased lactate levels of 4–15 mmol/L were found in the blood (5/5) and the cerebrospinal fluid (CSF) (2/2).
mtDNA-associated Leigh syndrome
The genotypic and phenotypic features of these 31 patients (18 male; 13 female) grouped into three distinct subgroups are outlined in table 1. The median age of onset was 11 months (range: from intrauterine to 19 years). In addition to hypotonia, the most common neurological features were ataxia (17/31) and dyskinesia (16/31). Hypertonia and/or spasticity were less common (11/31). Ophthalmoplegia was found in eight patients (25.8%), and six patients developed heart disease, cardiomyopathy (5/6) and conduction defect (1/6), respectively. Three patients developed sensorineural hearing loss. Central hypoventilation and/or hyperventilation was seen in 15 patients, of whom 12 had brainstem lesions on neuroimaging. The brainstem was the second most affected part of the brain (17/30) after the basal ganglia (25/30).
Muscle pathology suggestive of mitochondrial myopathy was found in nine patients and included the following findings: COX deficiency (3), abnormal SDH staining (2), abnormal NADH staining (2), low Mg-ATPase staining (1), mitochondrial proliferation/ragged red fibres (4) and structurally abnormal mitochondria on electron microscopy (2).
Two distinct phenotypes caused by two different missense mutations at position m.8993 in the MT-ATP6 gene are described in more detail below.
All seven patients showed a severe phenotype with onset by 6 months of age. The mutation was homoplasmic or >90% heteroplasmic in all patients. Five of seven patients died by the age of 3 years (figure 2). The disease onset was characterised by hypotonia (6/7), muscle weakness (4/7) and failure to thrive (4/7). The patients developed dyskinesia (5/7), central hypoventilation (4/7), nystagmus (3/7) and epilepsy (3/7). Macular atrophy was seen in one patient. All patients had increased lactate levels in blood and CSF. Combined NADH and SDH deficiencies were found on muscle enzyme histochemistry in one patient, while another patient had non-specific findings of infiltration of macrophages and muscle fibre atrophy. Respiratory chain complex deficiencies were found in four patients, two of them had isolated complex V deficiency and two had generally low complex activities. Brain MRI (6/7) showed T2 signal hyperintensity and/or atrophy of the basal ganglia (5/6), midbrain (3/6), cerebellum (3/6), supratentorial white matter (2/6) and cerebral cortex (1/6).
As opposed to the severe phenotype of m.8993T>G, all four patients with T>C mutations had an attenuated phenotype. The mutation was homoplasmic or >90% heteroplasmic in all patients. All patients developed symptoms by the age of 1.5 years and all were alive at a median follow-up of 6.1 years (figure 2). The clinical phenotype was characterised by ataxia (4/4), delayed speech development and dysarthria (4/4), diminished deep tendon reflexes (2/4) and retinopathy (2/4). Lactate levels were normal in blood (4/4) and slightly increased in CSF (2/4). Muscle fibre degeneration was found on biopsy in one patient. Two patients had normal respiratory chain enzyme activities, one had isolated complex V deficiency and another had generally low complex activities. Brain neuroimaging revealed signal changes and/or atrophy restricted to the basal ganglia (figure 2).
Phenotypic differences and overlaps between mtDNA and nDNA-associated Leigh syndrome
No significant differences were seen in terms of age of onset or disease outcome between these two major groups. Patients with mtDNA mutations were more likely to develop ataxia (p=0.004), while patients with nDNA mutations were more likely to develop sensorineural hearing loss (p=0.046). Ophthalmoplegia and cardiomyopathy were more common in the mtDNA compared with the nDNA group without reaching statistical significance (p=0.058 and p=0.200, respectively).
Patients with complex I deficiency due to mutations in either structural or assembly proteins (MT-ND and NDUF subgroups) represented 25% of our cohort. These patients had significantly higher occurrence of cardiac involvement (p=0.001) and ocular findings (p=0.023) compared with the rest of the cohort.
Distinct phenotypic features and phenotypic overlaps across the seven most common genetic subgroups, that is, SERAC1, MT-ATP6, MT-ND, NDUF, SURF1, SLC19A3 and SUCLA2, are summarised in figure 3. Survival outcomes of these genetic subgroups (number of patients, median, min, max) are shown in figure 4. In addition to the m.8993T>G-associated outcomes described earlier, poor survival outcomes were found in patients with (A) SLC19A3 mutations who did not receive treatment with thiamine and/or biotin: 8 of 12 patients died at a median age of 1 month; (B) SURF1 mutations: 5 of 8 patients died at a median age of 2 years; and (C) SERAC1 mutations: 4 of 5 patients died at a median age of 10.5 years.
Our study included 96 patients with genetically confirmed Leigh syndrome diagnosed and followed in eight centres in Northern and Western Europe. This is, to our knowledge, the largest phenotype-genotype correlation study in Leigh syndrome to be performed on systematically evaluated patients. We identified distinctive as well as overlapping phenotypic features across the genetic subgroups.
We analysed the different phenotypes caused by missense mutations in the MT-ATP6, m.8993T>C and m.8993T>G, and found the following novel correlations: patients with the m.8993T>G mutation had early onset, before 6 months, and poor disease outcome with death by 3 years of age. They also more frequently had epilepsy, failure to thrive, dyskinesia and brainstem dysfunction. Patients with m.8993T>C mutation had later debut, longer survival and less severe neurological outcome. Patients with the m.8993T>C mutation showed isolated striatal lesions radiologically, as opposed to lesions in multiple brain areas both supratentorially and infratentorially found in patients with the m.8993T>G mutation.
The percentage of patients with mutations in MT-ND genes was higher in our study compared with previous studies.13 22 We found that patients with mutations in MT-ND and NDUF genes with complex I deficiency shared clinical features, which differed from the rest of the cohort, such as significantly higher occurrence of cardiac and ocular involvement. These patients also showed similar radiological involvement of multiple deep grey matter structures, often with sparing of the cerebellum. These findings underline the importance of identifying the biochemical defect in oxidative phosphorylation disorders, as similar metabolic phenotypes often lead to similar clinical and radiological phenotypes despite very different genetic mechanisms.
Leigh syndrome is considered to be the most common phenotype among children with mitochondrial disease due to complex I deficiency.23–25 Other phenotypes include leukoencephalopathy,26 neonatal cardiomyopathy and encephalopathy,27 28 and fatal infantile lactic acidosis.16 24 Our patients with complex I defect presented with a relatively homogeneous phenotype characterised by the early onset of multiorgan disease as has been described in previous studies.25 29 This was typically characterised by central nervous system, respiratory, ocular, cardiac, auditory and occasionally renal involvement. Furthermore, we found patients with Leigh syndrome due to mutations in NDUF genes to have significantly higher risk of developing kidney disease or dysplasia.
Cardiomyopathy, hypertrophic or dilated, was found in 10% of our patient cohort and was twice as prevalent in patients with mtDNA mutations compared with the nDNA group. However, in all patients with mtDNA mutations, cardiomyopathy was not present at disease onset but developed later. Two of our patients presented with infantile hypertrophic cardiomyopathy at disease onset. These patients had mutations in NDUFS4 and NDUFA2 confirming previous reports.17 18 Heart disease alone was not related to poorer survival, neither in the NDUF group, nor in the entire study population, in contrast to previous studies that have correlated heart disease with poorer survival in patients with mitochondrial diseases.12
Our patients with nuclear-encoded complex I deficiency had the characteristic symmetrical deep grey matter lesions, but also showed lesions in the cerebral cortex significantly more often than the rest of the cohort. These lesions included cortical atrophy, T2-signal hyperintensities or stroke-like lesions. Radiological involvement of the cortex, commonly reflected by global atrophy, was found in 12% of patients with Leigh syndrome regardless of genetic cause in one study.30 Neuropathology studies in Leigh syndrome suggest that the characteristic striatal and brainstem lesions are due to primary energy deprivation.22 The pathological process causing cortical lesions appears to differ and has been considered as a neurodegenerative process causing neuronal loss and atrophy.22 The cortical lesions pertaining to either signal changes or stroke-like lesions seen in our patients cannot entirely be attributed to secondary neurodegeneration, but suggest a different or complementary pathogenic mechanism. Supratentorial stroke-like lesions in combination with brainstem lesions are commonly seen in mtDNA-encoded complex I deficiency.31 Increased complex I gene expression in the cortex has been seen during cerebral development. This is related to intense neurogenesis, neuronal differentiation and migration.32 Our findings could thus support the hypothesis that proposes an important role for complex I activity in the neurogenesis and neuroplasticity of specific areas in the human brain; compromised complex I gene expression may therefore lead to primary cortical degeneration.33
The prognosis of Leigh syndrome due to nuclear-encoded complex I deficiency is poor, especially in patients with core subunit mutations. Thus far, no clear association between the prognosis and the underlying genetic, neuroimaging or biochemical defects exists.23 25 Our studied patients had variable lifespan from early death to survival beyond the fifth decade. Early onset is associated with poorer survival, but this is true for Leigh syndrome regardless of the genetic cause.20 24 In addition, patients in our study who died at preschool age shared the clinical features of early-onset multisystem disease with epileptic seizures, central hypoventilation, and cardiac and renal involvement.
Muscle histopathology is an important diagnostic tool in suspected mitochondrial disease, along with respiratory chain enzyme activities. Specific myopathic findings are linked to specific mitochondrial myopathies and to certain mtDNA defects in particular.34 In our study, the only genetic subgroup with consistently abnormal histopathological findings on muscle biopsy was the SURF1 subgroup showing COX deficiency and mitochondrial proliferation as described in the literature.35 In the total cohort, only 32% of patients with either mtDNA or nDNA-associated Leigh syndrome had histopathological findings in muscle suggestive of mitochondrial disease. Furthermore, 27% of our cohort had normal respiratory chain enzyme activities, and 15% had normal lactate levels in both blood and CSF. Patients with mutations in the NDUF genes showed combined complex deficiencies. This has been previously shown with mutations in complex I subunit genes (either mtDNA or nDNA) and attributed to disruption of the respiratory chain supercomplexes by the truncated complex.36 37
Our study describes the largest cohort of Leigh disease to date and adds considerably to existing knowledge concerning phenotype-genotype associations. We provide new insights into the phenotypic panorama of certain genotypes considered to be common causes of Leigh syndrome, for example, mutations in the MT-ATP6 and NDUF genes. Further, we have identified important phenotypic differences between mtDNA and nDNA-associated Leigh syndrome and showed that diagnosis usually requires the combination of different investigations, such as laboratory and genetic testing, in addition to thorough clinical and radiological evaluation. The discovery of new genetic causes makes phenotype-genotype correlations difficult and the diagnosis of Leigh disease challenging. Studies such as ours are important therefore to improve recognition of this disease, understanding its outcome and to ensure that potential treatments can be properly evaluated.
Contributors All authors have contributed to the planning, conduct and reporting of the work described in this paper. Moreover, KS coordinated the conduct of this work and ND is responsible for the overall content as guarantor.
Competing interests None declared.
Ethics approval Ethical Committee at the University of Gothenburg and local ethical committees at the respective centres as per the standing regulatory requirements.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.